ETF Series Solutions's Defiance Nasdaq Junior Biotechnology ETF (IBBJ) has disclosed 230 total holdings in their latest N-PORT filing with the SEC for the
portfolio date of 2021-09-30. The current portfolio value is calculated to be $7.00 Mil, only including common equities, preferred
equities, ETFs, options and warrants for equities. The turnover rate is 3%.
Defiance Nasdaq Junior Biotechnology ETF (IBBJ)'s
Total Assets is $7.25 Mil , Total Liabilities is $2,850.00 , Net Assets is $7.25 Mil.
In Defiance Nasdaq Junior Biotechnology ETF (IBBJ)'s current portfolio as of 2021-09-30, the top 5 holdings are
Intellia Therapeutics Inc (NTLA), Zai Lab Ltd (ZLAB), BridgeBio Pharma Inc (BBIO), Medpace Holdings Inc (MEDP) and Beam Therapeutics Inc (BEAM),
not including call and put options.
Defiance Nasdaq Junior Biotechnology ETF (IBBJ) did not buy any new stocks in the current portfolio.
Please visit the "Current Portfolio" tab to see the ETF's current and past N-PORT holdings for Defiance Nasdaq Junior Biotechnology ETF (IBBJ), as well as holding map,
valuations for each stock, which positions are undervalued, have low PE Ratios, are considered high quality and recently traded at 52-week lows, etc.
Please visit the "Stock Picks" tab to see the ETF's latest trades and stock picks for Defiance Nasdaq Junior Biotechnology ETF (IBBJ), which include data from form N-PORT.
Please visit the "Summary" page to see the top 10 holdings, recent stock picks, performance, sector / industry breakdown details, as well as past holding history summary for Defiance Nasdaq Junior Biotechnology ETF.